LEADER 04040nam  2201189z- 450 
001 9910557609703321
005 20231214133440.0
035   $a(CKB)5400000000045305
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/79677
035   $a(EXLCZ)995400000000045305
100   $a20202203d2022      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aInnovation and Evidence for Achieving TB Elimination in the Asia-Pacific Region
210   $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022
215   $a1 electronic resource (238 p.)
311   $a3-0365-2551-3 
311   $a3-0365-2550-5 
330   $aThe World Health Organization?s (WHO) END-TB strategy has set the world on course to climb the highest of medical mountains by 2035, with a targeted peak of reductions in TB deaths by 95%, TB cases by 90%, and no burdens of catastrophic expenses on families due to TB. Eliminating TB in the Asia-Pacific region, which has 62% of all estimated TB patients globally, will require innovation, rigorous research, and sustained investment. This special issue connects original research and viewpoints on pertinent approaches for improving TB care and prevention in the Asia-Pacific region.
606   $aHumanities$2bicssc
606   $aSocial interaction$2bicssc
610   $apediatric TB
610   $averbal screening
610   $acontact tracing
610   $aresources
610   $asputum
610   $ahealth promotion
610   $aoperational research
610   $aindigenous population
610   $amultidrug-resistant tuberculosis
610   $ahousehold contact
610   $ascreening
610   $aTB diagnosis
610   $ayield
610   $aoperations research
610   $acontacts
610   $acontact investigation
610   $aMDR-TB
610   $apublic-private mix model
610   $apublic-private partnership
610   $amissing cases
610   $aSORT IT
610   $aTB diagnostics
610   $alaboratory methods
610   $acase detection
610   $aXpert Ultra
610   $aSTR
610   $aBangladesh regimen
610   $atuberculosis
610   $apost-tuberculosis morbidity and mortality
610   $aTB preventive therapy
610   $alatent TB infection
610   $aAsia Pacific
610   $arifapentine-isoniazid
610   $aincidence
610   $ahousehold contacts tracing
610   $aEnd TB
610   $asustainable development goals
610   $aSouth-East Asia
610   $aWestern Pacific Region
610   $anational TB program
610   $asocio-economic determinants
610   $adiabetes mellitus
610   $aTB-DM
610   $aadverse drug reactions
610   $aunfavourable outcome
610   $alymph node TB
610   $abone TB
610   $aTB elimination
610   $aextrapulmonary tuberculosis
610   $aprivate sector
610   $aintermediary agency
610   $areferral
610   $anotification
610   $aViet Nam
610   $aactive case finding
610   $acommunity outreach
610   $aIndonesia
610   $akey population
610   $ainnovation
610   $aTB REACH
610   $acommunity health workers
610   $amobile X-ray screening
610   $aTB
610   $achest X-ray
610   $aactive TB case-finding
610   $adiagnostic algorithm
615  7$aHumanities
615  7$aSocial interaction
700   $aDuCros$b Philipp$4edt$01314050
702   $aHussain$b Hamidah$4edt
702   $aViney$b Kerri$4edt
702   $aDuCros$b Philipp$4oth
702   $aHussain$b Hamidah$4oth
702   $aViney$b Kerri$4oth
906   $aBOOK
912   $a9910557609703321
996   $aInnovation and Evidence for Achieving TB Elimination in the Asia-Pacific Region$93645779
997   $aUNINA